Drug Profile
Influenza virus vaccine trivalent - Protein Sciences Corporation
Alternative Names: ASP-7374; FluBlok; Seasonal influenza vaccine - Protein Sciences Corporation; Trivalent recombinant baculovirus-expressed hemagglutinin influenza vaccine (FluBlok); UMN-05; UMN-0502Latest Information Update: 05 Nov 2023
Price :
$50
*
At a glance
- Originator Protein Sciences Corporation
- Developer Astellas Pharma; Ildong Pharmaceutical; Laboratorios Liomont; Protein Sciences Corporation; UMN Pharma
- Class Influenza virus vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Marketed Influenza virus infections
Most Recent Events
- 28 May 2019 No recent reports of development identified for preclinical development in Influenza-virus-infections(Prevention) in China (IM, Injection)
- 28 May 2019 No recent reports of development identified for preclinical development in Influenza-virus-infections(Prevention) in Hong Kong (IM, Injection)
- 28 May 2019 No recent reports of development identified for preclinical development in Influenza-virus-infections(Prevention) in Singapore (IM, Injection)